CN104248694A - Pharmaceutical composition and pharmaceutical preparation as well as application of pharmaceutical preparation - Google Patents
Pharmaceutical composition and pharmaceutical preparation as well as application of pharmaceutical preparation Download PDFInfo
- Publication number
- CN104248694A CN104248694A CN201410478289.8A CN201410478289A CN104248694A CN 104248694 A CN104248694 A CN 104248694A CN 201410478289 A CN201410478289 A CN 201410478289A CN 104248694 A CN104248694 A CN 104248694A
- Authority
- CN
- China
- Prior art keywords
- content
- pharmaceutical composition
- pharmaceutical preparation
- weight portion
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition and a pharmaceutical preparation and application of the pharmaceutical preparation. The pharmaceutical composition comprises the following raw materials in parts by weight: 100 parts of toad skin, 100-400 parts of frankincense, 100-400 parts of myrrh, 100-400 parts of elephant skin, 100-400 parts of dragon's blood, 100-400 parts of saffron, 100-500 parts of notoginseng, 100-500 parts of plum slice, 100-500 parts of dittany bark, 100-300 parts of cuttlebone, 40-130 parts of pearl, 100-300 parts of Asparagusbrachyphylus Turcz and 100-340 parts of Belamcanda chinensis. The invention further relates to a pharmaceutical preparation containing the pharmaceutical composition. The invention further relates to application of the pharmaceutical preparation to preparation of medicines for treating a venous ulcer disease of a lower limb. When the pharmaceutical composition and the pharmaceutical preparation thereof are used for treating the venous ulcer disease of the lower limb, the cure rate is high and the therapeutic effect is significant.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, and the pharmaceutical preparation containing this pharmaceutical composition, and the application of this pharmaceutical preparation.
Background technology
Current varicose veins of the lower extremity is the most important disease of Venous system, is also one of modal disease in limb vessel disease.
In order to understand generation and the development of varicose veins of the lower extremity better, etiology and treatment basis, first must be familiar with dissection and the physiological situation of superficial veins of lower limb.
1, wall of vein weakness and septal defect: wall of vein is relative weak, can expand under venous pressure effect, the expansion of lobe Dou Chu causes original vein valve without tight closure, there is valve insufficiency, backflow of blood, due to valve dysplasia or disappearance, can not play and effectively prevent refluence effect, cause morbidity.
2, intravenous pressure holding raises for a long time: venous blood itself is due to action of gravity, certain pressure is produced to valve, can not cause damage to it under normal circumstances, but when intravenous pressure durations raises, valve can bear overweight pressure, relax gradually, prolapse, make it incompetence, this is more common in work of standing for a long time, the crowd of heavy physical labour, gestation, chronic cough, prolonged constipation etc.
3, be secondly age, sex: because limbs venous pressure only reaches most Gao Shifangda maximum pressure in body length, preadolescence health is not high, therefore vein bore is less, venectasia can be prevented, although suffer from serious varicosis so had before 30 years old, but great majority increase with the age, and wall of vein and valve lose its tension force gradually, and symptom aggravation forces patient to seek medical advice.
Varicosis is common with women, may can bring out due to gestation or increase the weight of varicosis.But there is no the women of gestation, its sickness rate is (man: female=1:3) higher than male also, its reason may be that gynecoid pelvis is more roomy, blood vessel structure overbending, menstrual phase, trimester of pregnancy and menopause time that endopelvic vein is increased is congested, trimester of pregnancy easily occur another reason cirsoid be due to trimester of pregnancy extremity superficial vein tension force reduce, make its be easy to expansion, this situation can be recovered in puerperal.
If superficial veins of lower limb varicose can not get effectively controlling, varicose ulcer of lower extremity can be shown time late, varicose ulcer of lower extremity is common peripheral angiopathy, sickness rate is up to 1% ~ 2%, ulcer does not heal throughout the year or recurs more afterwards, be one of intractable diseases, cause very big inconvenience to the work of patient and life, the ulcer often caused because of varicosis and seeking medical advice.But also there is no Chinese medicine composition and the preparation thereof that effectively can treat this disease now.
Therefore, be badly in need of now a kind of can the pharmaceutical composition of cure varicose vein of lower limb ulcer and preparation thereof.
Summary of the invention
The object of the invention is cannot the defect of cure varicose vein of lower limb ulcer in order to overcome in prior art, provides a kind of pharmaceutical composition, and the pharmaceutical preparation containing this pharmaceutical composition, and the application of this pharmaceutical preparation.
The present inventor finds under study for action, pharmaceutical composition contains following raw material: Bufo siccus clothing, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, Stigma Croci, Radix Notoginseng, borneol, stereotyped writing cattle, Endoconcha Sepiae, Margarita, grab Pheretima and Rhizoma Belamcandae, wherein, relative to the Bufo siccus clothing of 100 weight portions, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, croceous content is 100-400 weight portion separately, Radix Notoginseng, borneol, the content of stereotyped writing cattle is 100-500 weight portion separately, Endoconcha Sepiae, the content of grabbing Pheretima is 100-300 weight portion separately, the content of Margarita is 40-130 weight portion, the content of Rhizoma Belamcandae is 100-340 weight portion, by this pharmaceutical composition and be used for the treatment of veins of lower extremity containing the pharmaceutical preparation of this pharmaceutical composition and fester disease, veins of lower extremity can be significantly improved to fester the cure rate of disease, and it is evident in efficacy.
Therefore, to achieve these goals, the invention provides a kind of pharmaceutical composition, this pharmaceutical composition contains following raw material: Bufo siccus clothing, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, Stigma Croci, Radix Notoginseng, borneol, stereotyped writing cattle, Endoconcha Sepiae, Margarita, grab Pheretima and Rhizoma Belamcandae, wherein, relative to the Bufo siccus clothing of 100 weight portions, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, croceous content is 100-400 weight portion separately, Radix Notoginseng, borneol, the content of stereotyped writing cattle is 100-500 weight portion separately, Endoconcha Sepiae, the content of grabbing Pheretima is 100-300 weight portion separately, the content of Margarita is 40-130 weight portion, the content of Rhizoma Belamcandae is 100-340 weight portion.
Preferably, relative to the Bufo siccus clothing of 100 weight portions, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, croceous content are 150-230 weight portion separately, the content of Radix Notoginseng, borneol, stereotyped writing cattle is 150-260 weight portion separately, Endoconcha Sepiae, the content of grabbing Pheretima are 140-270 weight portion separately, the content of Margarita is 60-100 weight portion, and the content of Rhizoma Belamcandae is 170-260 weight portion.
On the other hand, present invention also offers a kind of pharmaceutical preparation containing aforementioned pharmaceutical compositions.
The third aspect, present invention also offers said medicine preparation in the application of festering in the medicine of disease for the preparation for the treatment of veins of lower extremity.
Pharmaceutical composition of the present invention and pharmaceutical preparation be treatment veins of lower extremity fester disease time, the effect of promoting the flow of QI in the collateral by warming the meridian, promoting blood circulation and breaking stagnation, reducing swelling and alleviating pain, convergence ulcer surface can be played, veins of lower extremity can be significantly improved and to fester the cure rate of disease, and evident in efficacy.
Other features and advantages of the present invention are described in detail in detailed description of the invention part subsequently.
Detailed description of the invention
Below the specific embodiment of the present invention is described in detail.Should be understood that, detailed description of the invention described herein, only for instruction and explanation of the present invention, is not limited to the present invention.
The invention provides a kind of pharmaceutical composition, this pharmaceutical composition contains following raw material: Bufo siccus clothing, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, Stigma Croci, Radix Notoginseng, borneol, stereotyped writing cattle, Endoconcha Sepiae, Margarita, grab Pheretima and Rhizoma Belamcandae, wherein, relative to the Bufo siccus clothing of 100 weight portions, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, croceous content is 100-400 weight portion separately, Radix Notoginseng, borneol, the content of stereotyped writing cattle is 100-500 weight portion separately, Endoconcha Sepiae, the content of grabbing Pheretima is 100-300 weight portion separately, the content of Margarita is 40-130 weight portion, the content of Rhizoma Belamcandae is 100-340 weight portion.
Preferably, relative to the Bufo siccus clothing of 100 weight portions, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, croceous content are 150-230 weight portion separately, the content of Radix Notoginseng, borneol, stereotyped writing cattle is 150-260 weight portion separately, Endoconcha Sepiae, the content of grabbing Pheretima are 140-270 weight portion separately, the content of Margarita is 60-100 weight portion, and the content of Rhizoma Belamcandae is 170-260 weight portion, can improve veins of lower extremity further and to fester the cure rate of disease.
In the present invention, weight portion refers to the dry weight basis of each crude drug.
In the present invention, Bufo siccus clothing is called: Cutis Bufonis, toad are sloughed off, i.e. the epidermis taken off of Bufonidae animal (Veneum Bufonis) Bufo siccus oneself.A Bufo siccus can take off 10-40 for 1 year and open skin, and north-south climate is different, and environment differs and variant.
In the present invention, the resin that the bark that Olibanum (OLIBANUM) is olive subject plant Boswellia carterii (Boswellia carterii Birdw) and/or congener (as Bao Da Boswellia carterii Boswellia bhawdajiana Birdw. and wild Boswellia carterii Boswellia neglecta M.Moore) oozes out.Olibanum is in long avette emulsus, similar round granule or be bonded into the irregular block differed in size, surperficial yellow-white, translucent, is had yellow-white powder; then color burn stored for a long time, matter is crisp, and heat is softened; the plane of disruption has hyaloid or wax sample gloss, the special fragrance of tool, mildly bitter flavor.Slightly see melting point mainly through being put by raw material in pot to fry with slow fire to surface, slightly in yellow, taking-up cools and obtains; Or fry when dissolving to surface, spray rice vinegar, continue to fry to outer bright light saturating, take out to cool and obtain.
In the present invention, Myrrha (MYRRHA) is the dry resin of olive subject plant Herba Violae tree (Commiphora myrrha Engl.) and/or congener (as breathed out Herba Violae tree Commiphora molmol Engl.).Natural Myrrha is irregular particle agglomerate.Surface yellowish-brown or rufous, nearly translucent portion is brownish black, is had yellow dust.Matter heavily fortified point is crisp, and the plane of disruption is irregular, matt: have special fragrance, bitter in the mouth and micro-pungent.Gum opoponax is irregular bulk and granule, coheres the agglomerate becoming to differ in size more, and surperficial brown color is to sepia, opaque, and matter is solid or loose, has special fragrance, bitter in the mouth and have stickiness.Mainly through being stabbed by tree, resin is oozed out naturally by wound or crack mouth.Be just yellowish white liquid, fade to rufous lump in atmosphere, obtain after drying.
In the present invention, Corium elephatis is the skin of Elephantidae animal elephant, and elephant (Elephas maximus L.) African elephant (Elephas africanus Blumenbach) is distributed in the ground such as India, Indonesia, Sri Lanka, Thailand, Burma, Malaysia and Yunnan Province of China be southern.
In the present invention, Sanguis Draxonis is the resin in babassu Sanguis Draxonis fruit and rattan; Original shape state: Sanguis Draxonis, perennial evergreen liana, reaches 10-20m, and stem is by sheath and all over raw spine, winglike compound leaf is in branch top alternate, sometimes near to life in bottom; Lobule alternate, wire lanceolar, is about 20-30cm, wide about 3cm, the sharp point of tip, and base portion is narrow, and arteries and veins 3 goes out parallel; Petiole and the sharp thorn of rachis tool, spadix, opens flaxen crown flower, unisexuality, dioecism; Perianth 6, lines up 2 and takes turns; Male flower stamen 6, the long taper of flower pesticide; Female flower has parastamen 6, gynoecium 1, ampuliform, and ovary is slightly in ovum shape, and close by scale, style is short, stigma 3 drastic crack.Fruit drupe shape, ovum shape is spherical, and footpath is about 2-3cm, russet, the yellow scale of tool, and fruit includes the fluid resin of dark redness of the skin or complexion, often oozes out by under scale, as clot sample after dry, 1, seed.Medical material latin name: Resina Draconis, plant latin name: Daemonorops draco Bl..
In the present invention, Stigma Croci is the dry stigma of irides Stigma Croci (Crocus sativus L.), and for Pharmacopoeia of the People's Republic of China nineteen ninety version is recorded, morphological characteristic: perennial root herbaceous plant, without the aerial stem of plant.Underground bulb is oblate spheroid, loose like Bulbus Allii Cepae, appearance by which floor brown film quality scale is surrounded, and interior is milky entity meat, the brown link of tool many, on joint sprout, each bud by multilamellar film quality scale, terminal bud (main bud) 1-4, greatly and obviously, be positioned at bulb top, lateral bud is many and little, is distributed on each joint.Leafage is raw, and linear, stockless, long 15-45 centimetre, accidental more than 50 centimetres, wide 0.2-0.4 centimetre, tip is sharp, smooth, Quan Yuan, and cross section is warp shape, every strain 2-13 clump, and every clump has 2-15 sheet leaf, and base portion has the translucent scale of 3-5 sheet.Hua Dingsheng, diameter 4-6 centimetre, 6, perianth, obovate, lavender, thin tube-like, stamen 3, flower pesticide is large, yellow, base portion flechette-type, gynoecium 1, carpel symphysis, ovary is the next, and style is elongated, faint yellow, stigma 3 drastic crack, expand in funnel-form, long 2-3 centimetre, stretch out outside cylinder, sagging, peony, glossy, the special fragrance of tool.
In the present invention, Radix Notoginseng is the root of panax araliaceae plant, plant latin name: Panax notoginseng (Burk.) F.H.Chen ex C.Chow [P.pseudo-ginseng Wall.Vart.Notoginseng (Burk.) Hoo et Tseng], gather and store: general plantation 4 years results, the title " spring seven " gathered in the crops the 8-9 month, quality is good, output is high, the title " winter seven " that November gathers in the crops, of poor quality, product is low.The tuber dug, cleans earth, places by size, Exposure to Sunlight or fire dry (36-38 DEG C) 2-3d, about sixty percent dry time, by supporting root, fibrous root, rhizome is cut respectively, then carries out Exposure to Sunlight or fire baking 2-3d respectively, carry out rubbing or put into rotating cylinder to roll, make it rub mutually, take out and shine again or dry, 4-5 time repeatedly, a little Herba Poae Sphondylodis or Semen phaseoli radiati can be added last 1 time, until the smooth rounding of tuber, parch and get final product.
Phytomorph is: perennial herb, and up to 30-60cm, rhizome is short, has old stem remaining trace; The sturdy meat of root, turbination or short cylindrical shape, be about 2-5cm, and diameter is about 1-3cm, has several supporting roots, and crust yellow green is to brown color, and stem is upright, is bordering on cylindrical; Glabrous, green or be with the thin vertical stripe of most purple, palm volt compound leaf, 3-4 piece of wheel is born in stem end; Petiole is elongated, and surface is without hair; Lobule 3-7 piece; Vanelets is oval is about 5-14cm, wide 2-5cm to oval shape obovate, and several pieces are larger in central authorities, the most lower 2 minimum, the long point of tip, base portion subcircular or both sides unbecoming, there is serration at edge, the little seta of the even tool of increment, surface has spinelet hair along the pulse, and two sides is all bordering on without hair sometimes; Tool petiolule.Total bennet is extracted out from stem end petiole central authorities, uprightly, and long 20-30cm; Umbel pushes up life separately, and diameter is about 3cm; Spend majority, both sexes, unisexual flower and hermaphrodite flower coexist sometimes; Pedicel is carefully short, and base portion has flakey bract; Calyx is green, usual 5 fissures of tip; Petal 5, oval shape is avette, tip point, yellow green; Stamen 5, flower pesticide is oval, and life carried by medicine, and interior to lobe, filigree is linear; Gynoecium 1, ovary is the next, and Room 2, spend 2 pieces, base portion symphysis, the smooth or nick of floral disc; Drupe berry shape, is bordering on kidney shape, is about 6-9mm; Green time tender.Red time ripe, seed 1-3, spherical, seed coat white.The florescence 6-8 month; The fruit phase 8-10 month.
In the present invention, borneol is the fresh branch and leaf of canella borneol tree (Typus physiologions Cinnanloni.), through steam distillation, collects gold-plating fluid, the crystallization of precipitation.It is the Powdered crystallization of white translucent; Gas delicate fragrance, acrid in the mouth, cool; Tool volatility, lights generation black smoke, and with the flame of yellow.
In the present invention, stereotyped writing cattle is the root bark of rutaceae shaggy-fruited dittany and Dictamnus angustifolius.Medicine latin name: Dictamni Cortex.
In the present invention, Endoconcha Sepiae is the dry inner shell of Sepiidae animal sepiella maindroni de Rochebrune (Sepiella maindroni de Rochebrune) or golden cuttlefish (Sepia esculenta Hoyle).Collect the bone-shaped inner shell of sepiellae seu sepiae fish, cleaning, drying.
In the present invention, Margarita is the Margarita that in the shells such as the female shellfish in Pteriidae animal Hepu, Pinctada margaritifera, Pinctadamaxima (Jameson), Pinctada chemnitzi or Unionidae animal hydriopsis cumingii, cristaria plicata, anodonta woodiana pacifica, outer embrane irriate is formed.Latin name: Pernulo.
In the present invention, grabbing Pheretima is the tuber that liliaceous plant climbs up by holding on to Radix Asparagi.Plant latin name: Asparagusbrachyphylus Turcz..
In the present invention, Rhizoma Belamcandae is the root stock of irides Rhizoma Belamcandae (formal name used at school: Belamcanda chinensis (L.) Redout é), and Rhizoma Belamcandae is perennial herb, and root stock is irregular bulk, tiltedly stretches, yellow or yellowish-brown; Fibrous root is most, and band is yellow, and stem is upright, and stem height 1-1.5 rice is solid.
In the present invention, above-mentioned raw materials used also can conventionally the concocting of having cooked of can being purchased.
In the present invention, the form of pharmaceutical composition does not have special restriction, as long as the form of pharmaceutical composition can be convenient to external, can being such as powder and/or granule, during in order to make pharmaceutical composition and pharmaceutical preparation external skin ulcer surface thereof, can contacting more fully with this ulcer surface, be absorbed by the skin better, preferably, described pharmaceutical composition is powder, and the particle mean size of this powder is 80-120 order.
Pharmaceutical composition of the present invention can by obtaining above-mentioned various raw material mixing.As long as the condition of mixing makes various raw material according to ratio mix homogeneously of the present invention.
It should be noted that herein, above-mentioned various raw material can be carried out being ground to preferred particle size range in the present invention again according to after content range mixing of the present invention in the present invention, also the various raw materials being ground to particle size range of the present invention in advance can be mixed to get according to proportioning of the present invention.Wherein, described raw material or pharmaceutical composition being ground to 80-120 object method can be the Chinese medicine Ginding process of this area routine, can also comprise before the grinding and above-mentioned each raw material or pharmaceutical composition being dried.
On the other hand, present invention also offers a kind of pharmaceutical preparation, this pharmaceutical preparation contains aforementioned pharmaceutical compositions.
According to pharmaceutical preparation of the present invention, wherein, special restriction is not had to the dosage form of pharmaceutical preparation, as long as described pharmaceutical preparation contains aforementioned pharmaceutical compositions and can be used in external, such as this pharmaceutical preparation can be powder, when for powder, it should be appreciated by those skilled in the art, aforementioned pharmaceutical compositions directly can be used as powder.
According to pharmaceutical preparation of the present invention, wherein, this pharmaceutical preparation can also be unguentum, and when for unguentum, this unguentum can contain aforementioned pharmaceutical compositions and adjuvant.With the gross weight of this unguentum for benchmark, the content of described pharmaceutical composition is 10-90 % by weight, and the content of described adjuvant is 10-90 % by weight, and wherein, described adjuvant can be the adjuvant for the preparation of unguentum of this area routine, such as, can be vaseline.The preparation method of unguentum can be the method for the preparation of unguentum of this area routine.Such as can comprise pharmaceutical composition and adjuvant mixing.
The temperature of described mixing can be 100-130 DEG C, and the time of mixing can be 10-60 minute.
The third aspect, present invention also offers said medicine preparation in the application of festering in the medicine of disease for the preparation for the treatment of veins of lower extremity.
Pharmaceutical preparation of the present invention is when reality uses, and for adult, in pharmaceutical composition, dosage is every day 2 times, each 0.5-3g,
Pharmaceutical composition of the present invention and pharmaceutical preparation thereof be used for the treatment of veins of lower extremity fester disease time, the effect of promoting the flow of QI in the collateral by warming the meridian, promoting blood circulation and breaking stagnation, reducing swelling and alleviating pain, convergence ulcer surface can be played, thus veins of lower extremity can be significantly improved to fester the cure rate of disease.
In the present invention, cure rate refers to that symptom in each treatment group disappears completely and symptom obviously alleviates number accounts for the ratio of this treatment group total treatment numbers.
Embodiment
In the following Examples and Comparative Examples, the processing method of raw material used is as follows:
Respectively by the Bufo siccus clothing be purchased, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, Stigma Croci, Radix Notoginseng, borneol, stereotyped writing cattle, Endoconcha Sepiae, Margarita, grab Pheretima and Rhizoma Belamcandae dries rear grinding, and with 100 object screen cloth screenings, select the siftage of each raw material for the preparation of pharmaceutical composition of the present invention.
Cure rate refers to that symptom in each treatment group disappears completely and symptom obviously alleviates number accounts for the ratio of this treatment group total treatment numbers.
Embodiment 1-4
Embodiment 1-4 is for illustration of pharmaceutical composition of the present invention
According to the consumption (all with parts by weight) shown in table 1, each raw material is mixed, respectively obtained pharmaceutical composition A 1-A4.
Table 1
| ? | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Comparative example 1 | Comparative example 2 |
| Pharmaceutical composition is numbered | A1 | A2 | A3 | A4 | D1 | D2 |
| Bufo siccus clothing | 100 | 100 | 100 | 100 | 0 | 100 |
| Olibanum | 150 | 180 | 230 | 400 | 150 | 150 |
| Myrrha | 150 | 180 | 230 | 400 | 150 | 150 |
| Corium elephatis | 150 | 190 | 230 | 100 | 150 | 0 |
| Sanguis Draxonis | 150 | 170 | 230 | 400 | 150 | 150 |
| Stigma Croci | 150 | 170 | 230 | 400 | 150 | 150 |
| Radix Notoginseng | 150 | 200 | 260 | 500 | 150 | 150 |
| Borneol | 150 | 150 | 260 | 100 | 150 | 150 |
| Stereotyped writing cattle | 150 | 160 | 260 | 100 | 150 | 150 |
| Endoconcha Sepiae | 140 | 200 | 270 | 100 | 140 | 140 |
| Margarita | 60 | 80 | 100 | 130 | 60 | 0 |
| Grab Pheretima | 140 | 200 | 270 | 100 | 140 | 140 |
| Rhizoma Belamcandae | 170 | 200 | 260 | 100 | 170 | 170 |
Comparative example 1-2
According to the consumption (all with parts by weight) shown in table 1, each raw material is mixed, obtained pharmaceutical composition D1-D2.
Embodiment 5-10
Embodiment 5-10 is for illustration of powder provided by the invention.
The pharmaceutical composition D1-D2 that the pharmaceutical composition A 1-A4 obtained by embodiment 1-4 and comparative example 1-2 obtains directly uses as powder, is renumberd by this powder as B1-B6;
Embodiment 11-16
Embodiment 11-16 is for illustration of unguentum provided by the invention.
Vaseline is heated to 110 DEG C, pharmaceutical composition D1-D2 prepared by the pharmaceutical composition A 1-A4 then prepared by embodiment 1-4 respectively and comparative example 1-2 joins in vaseline, endures 20 minutes at 110 DEG C, obtains unguentum C1-C6.
Wherein, with the gross weight of described unguentum for benchmark:
In embodiment 11, the content of A1 is 50 % by weight, and the content of vaseline is 50 % by weight;
In embodiment 12, the content of A2 is 70 % by weight, and the content of vaseline is 30 % by weight
In embodiment 13, the content of A3 is 30 % by weight, and the content of vaseline is 70 % by weight
In embodiment 14, the content of A4 is 50 % by weight, and the content of vaseline is 50 weight;
In embodiment 15, the content of D1 is 50 % by weight, and the content of vaseline is 50 % by weight.
In embodiment 16, the content of D2 is 50 % by weight, and the content of vaseline is 50 % by weight.
Experimental example
Experimental example is for illustration of the effect of pharmaceutical composition provided by the invention and preparation thereof.
(1) 120 men and women patients's (M-F is 1:1) with varicose veins of the lower extremity always rotten lower limb are in various degree selected.Be divided into 6 groups at random, often organize 20 people.Topical administration, powder B1-B6 is sprayed on rotten position along vein trend, and cover one deck Polypropylence Sheet or binder is fixed, change dressings every day 2 times, each dosage is 3g.Medication is observing effect after 8 days.
Curative effect judging standard: compared with before taking medicine, ulceration face is healed for symptom disappears completely completely, be labeled as zero, blood vessel elasticity recovery, inflammation elimination and ulceration face are reduced to symptom and obviously alleviate, be labeled as △, ulceration face area does not become symptom and is not improved, be labeled as ×, the therapeutic effect of 6 treatment groups is as shown in table 2.
Table 2
(2) 150 men and women patients's (M-F is 1:2) with varicose veins of the lower extremity always rotten lower limb are in various degree selected.Be divided into 6 groups at random, often organize 25 people.Topical administration, unguentum C1-C6 is sticked on rotten position along vein trend, and cover one deck Polypropylence Sheet or binder is fixed, change dressings every day 2 times, each dosage is 3g.Medication is observing effect after 8 days.
Curative effect judging standard: compared with before taking medicine, ulceration face is healed for symptom disappears completely completely, be labeled as zero, blood vessel elasticity recovery, inflammation elimination and ulceration face are reduced to symptom and obviously alleviate, be labeled as △, ulceration face area does not become symptom and is not improved, be labeled as ×, the therapeutic effect of 6 treatment groups is as shown in table 3.
Table 3
As can be seen from the measurement result of above experimental example, embodiment 1-4 compared with comparative example 1-2, the preparation that the pharmaceutical composition of embodiment 1-4 is prepared into be used for the treatment of veins of lower extremity fester disease time, cure rate is high, evident in efficacy.
Embodiment 1 is compared can find out with embodiment 4, the cure rate of embodiment 1 is all higher than embodiment 4, therefore, when the Bufo siccus clothing relative to 100 weight portions, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, croceous content are 150-230 weight portion separately, the content of Radix Notoginseng, borneol, stereotyped writing cattle is 150-260 weight portion separately, Endoconcha Sepiae, the content of grabbing Pheretima are 140-270 weight portion separately, the content of Margarita is 60-100 weight portion, when the content of Rhizoma Belamcandae is 170-260 weight portion, veins of lower extremity can be improved further and to fester the cure rate of disease.
Pharmaceutical composition of the present invention and pharmaceutical preparation thereof be used for the treatment of veins of lower extremity fester disease time, the effect of promoting the flow of QI in the collateral by warming the meridian, promoting blood circulation and breaking stagnation, reducing swelling and alleviating pain, convergence ulcer surface can be played, thus veins of lower extremity can be significantly improved to fester the cure rate of disease.
More than describe the preferred embodiment of the present invention in detail; but the present invention is not limited to the detail in above-mentioned embodiment, within the scope of technical conceive of the present invention; can carry out multiple simple variant to technical scheme of the present invention, these simple variant all belong to protection scope of the present invention.
It should be noted that in addition, each concrete technical characteristic described in above-mentioned detailed description of the invention, in reconcilable situation, can be combined by any suitable mode, in order to avoid unnecessary repetition, the present invention illustrates no longer separately to various possible compound mode.
In addition, also can carry out combination in any between various different embodiment of the present invention, as long as it is without prejudice to thought of the present invention, it should be considered as content disclosed in this invention equally.
Claims (9)
1. a pharmaceutical composition, it is characterized in that, this pharmaceutical composition contains following raw material: Bufo siccus clothing, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, Stigma Croci, Radix Notoginseng, borneol, stereotyped writing cattle, Endoconcha Sepiae, Margarita, grab Pheretima and Rhizoma Belamcandae, wherein, relative to the Bufo siccus clothing of 100 weight portions, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, croceous content is 100-400 weight portion separately, Radix Notoginseng, borneol, the content of stereotyped writing cattle is 100-500 weight portion separately, Endoconcha Sepiae, the content of grabbing Pheretima is 100-300 weight portion separately, the content of Margarita is 40-130 weight portion, the content of Rhizoma Belamcandae is 100-340 weight portion.
2. pharmaceutical composition according to claim 1, wherein, wherein, relative to the Bufo siccus clothing of 100 weight portions, Olibanum, Myrrha, Corium elephatis, Sanguis Draxonis, croceous content are 150-230 weight portion separately, and the content of Radix Notoginseng, borneol, stereotyped writing cattle is 150-260 weight portion separately, and Endoconcha Sepiae, the content of grabbing Pheretima are 140-270 weight portion separately, the content of Margarita is 60-100 weight portion, and the content of Rhizoma Belamcandae is 170-260 weight portion.
3. pharmaceutical composition according to claim 1 and 2, wherein, described pharmaceutical composition is powder, and particle mean size is 80-120 order.
4. a pharmaceutical preparation, is characterized in that, this pharmaceutical preparation contains the pharmaceutical composition in claim 1-3 described in any one.
5. pharmaceutical preparation according to claim 4, wherein, described pharmaceutical preparation is powder.
6. pharmaceutical preparation according to claim 4, wherein, described pharmaceutical preparation is unguentum.
7. pharmaceutical preparation according to claim 6, wherein, described unguentum is also containing adjuvant, and with the gross weight of this unguentum for benchmark, the content of described pharmaceutical composition is 10-90 % by weight, and the content of described adjuvant is 10-90 % by weight.
8. pharmaceutical preparation according to claim 7, wherein, described adjuvant is vaseline.
9. the pharmaceutical preparation in claim 4-8 described in any one is in the application of festering in the medicine of disease for the preparation for the treatment of veins of lower extremity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410478289.8A CN104248694B (en) | 2014-09-17 | 2014-09-17 | Pharmaceutical composition and pharmaceutical preparation and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410478289.8A CN104248694B (en) | 2014-09-17 | 2014-09-17 | Pharmaceutical composition and pharmaceutical preparation and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104248694A true CN104248694A (en) | 2014-12-31 |
| CN104248694B CN104248694B (en) | 2018-05-15 |
Family
ID=52184169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410478289.8A Active CN104248694B (en) | 2014-09-17 | 2014-09-17 | Pharmaceutical composition and pharmaceutical preparation and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104248694B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1522314A1 (en) * | 2002-06-26 | 2005-04-13 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases caused by vascular contraction or dilation |
| CN101347559A (en) * | 2008-07-02 | 2009-01-21 | 刘彦宾 | Medicament for treating ulcer of skin |
-
2014
- 2014-09-17 CN CN201410478289.8A patent/CN104248694B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1522314A1 (en) * | 2002-06-26 | 2005-04-13 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases caused by vascular contraction or dilation |
| CN101347559A (en) * | 2008-07-02 | 2009-01-21 | 刘彦宾 | Medicament for treating ulcer of skin |
Non-Patent Citations (6)
| Title |
|---|
| 吴月芝等: "中西医结合治疗臁疮62例", 《河北中西医结合杂志》 * |
| 彭怀仁: "《中医方剂大辞典第十册》", 31 March 1997 * |
| 种振岳等: "《静脉疾病实用手册》", 31 July 2010 * |
| 谢永玉: "《中医效验方荟萃》", 31 July 2011 * |
| 赵建波等: "《皮肤病妙法良方大全》", 31 May 2011 * |
| 邱德文等: "《贵州十大苗药研究》", 31 August 2008 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104248694B (en) | 2018-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011026267A1 (en) | Antiphlogistic, antioncotic and analgesic chinese herbal composition,preparative method and usage thereof | |
| CN103751663A (en) | Traditional Chinese medicine externally applied preparation for treating perianal eczema and preparation method thereof | |
| Jana et al. | Herbal Treatment To Skin Diseases: A Global Approach. | |
| CN105368609A (en) | Health care medicated soap | |
| CN102302745A (en) | Zedoary turmeric oil essence | |
| CN103919984A (en) | Traditional Chinese medicine composition for treating mammary gland hyperplasia | |
| CN104248694B (en) | Pharmaceutical composition and pharmaceutical preparation and its application | |
| WO2015003307A1 (en) | Traditional chinese medicament for promoting hair growth and preparation method | |
| CN103845678B (en) | A kind of pharmaceutical composition for treating infant's dermatitis | |
| CN105535243A (en) | Medicine for treating intractable constipation | |
| CN104689283A (en) | Medicine for treatment of spleen insufficiency damp-aggregating type chloasma and preparation method thereof | |
| CN103860976B (en) | A kind of pharmaceutical composition for the treatment of infant's dermatitis | |
| CN104257911A (en) | Pharmaceutical composition, pharmaceutical preparation and application thereof | |
| CN109381556A (en) | A kind of composition that treating pernio, preparation method and applications | |
| CN104147481B (en) | A kind of antipruritic external medicine composition and preparation method thereof | |
| CN107582633A (en) | Treat traditional Chinese medicine for outer use of nettle rash and preparation method thereof | |
| CN108714167B (en) | A Chinese medicinal preparation for external use for treating vitiligo, and its preparation method | |
| CN106822206A (en) | It is a kind of to treat pharmaceutical composition of neurodermatitis and preparation method thereof | |
| CN105497732A (en) | Lacrimal duct irrigation fluid for nursing of infantile congenital lacrimal duct obstruction | |
| CN104983939A (en) | Traditional Chinese medicine for treating arteriosclerosis obliterans | |
| CN105079295A (en) | Traditional Chinese medicine for treating insufficiency of heart and spleen | |
| Amin et al. | A general overview on Rosemarinus officinalis L.(Rosemary) as a medicinal plant | |
| CN104906272A (en) | Medicine for treating arteriolar nephrosclerosis | |
| CN109106877A (en) | A kind of prevention and treatment breast feeding women's heat evil stops up Chinese medicine composition, preparation method and the pharmaceutical preparation of Sheng type mazoitis | |
| CN103463542B (en) | Application of edible vinegar as liquor for removing scars and changing skin, liquor for removing scars and changing skin and preparation method of liquor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191223 Address after: 063000 No.136 Park Road, Fengrun District, Tangshan City, Hebei Province Patentee after: Jingshan Chinese medicine (Tangshan) Co. Ltd. Address before: 130032 Changchun Normal University hospital, Jilin, Changchun Co-patentee before: Sun Hao Patentee before: Jin Guang |
|
| TR01 | Transfer of patent right |